Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients
M. Veronica Dioverti, David C. Gaston, C. Paul Morris, Carol Ann Huff, Tania Jain, R. Brad Jones, Viki Anders, Howard M. Lederman, Jacqueline Saunders, Heba H. Mostafa, Robin K. Avery
Abstract
Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.
Topics & Concepts
MedicineVirologyViral replicationCoronavirusVirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCoronavirus disease 2019 (COVID-19)DiseaseInternal medicineInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCancer Immunotherapy and Biomarkers